ArticleCancer science2021
Low-dose decitabine plus venetoclax is safe and effective as post-transplant maintenance therapy for high-risk acute myeloid leukemia and myelodysplastic syndrome.
Article in Cancer science, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 70 citations in OpenAlex.
- Phase II study of dual epigenetic targeting with chidamide and azacitidine in patients with high-risk acute myeloid leukemia after allo-HSCT.Clinical epigenetics · 2025Trial
- Strategies to prevent post-transplant relapse in acute myeloid leukemia and myelodysplastic syndromes.International journal of hematology · 2026Review
- Chidamide plus venetoclax as effective and safe maintenance therapy in high-risk acute myeloid leukemia and myelodysplastic syndrome post-transplantation.Annals of hematology · 2026Article
- Post-transplant hypomethylating agents plus venetoclax maintenance improves survival in high-risk myeloid malignancies: A matched cohort study.Blood cancer journal · 2026Article
- BCL2 overexpression in donor lymphocytes reduces the risk of graft-versus-host disease.Blood advances · 2026Article
- Therapy of high-risk myelodysplastic syndromes.Bone marrow transplantation · 2026Review
- Post Hematopoietic Cell Transplantation Maintenance Therapy With Low-Dose Azacitidine in a Pediatric Population With High-Risk Myeloid Malignancies.Transplantation and cellular therapy · 2026Article
- Azacitidine monotherapy versus combination regimens as post-HSCT maintenance therapy in high-risk myeloid malignancies: a retrospective cohort study.International journal of hematology · 2026Article
- Outcomes of allogeneic hematopoietic stem cell transplantation from different donor types in primary refractory acute myeloid leukemia: a report from the ALWP of the EBMT.Bone marrow transplantation · 2026Article
- The ER Stress-related Gene Prognostic Signature for Predicting Chemosensitivity and Prognosis in AML.Recent patents on anti-cancer drug discovery · 2026Article
- Article
- Comparison of clinical outcomes between preemptive and maintenance therapy after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia.International journal of hematology · 2025Article
- Current scenario of allogeneic hematopoietic stem cell transplantation in adult patients with relapsed/refractory acute myeloid leukemia: a narrative review.Annals of hematology · 2025Review
- TP-0903 Suppresses Aurora A-PLK1 Signaling to Inhibit Proliferation of a Myelodysplastic Syndrome-Derived Cell Line.Cancer science · 2025Article
- Impact of Decitabine Conditioning on Allo-HSCT Outcomes in AML and Intermediate-to-High-Risk MDS Patients in Remission.Cancer medicine · 2025Article
- Review
- [Progress in hematopoietic stem cell transplantation for acute myeloid leukemia].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2025Review
- Post-stem cell transplant maintenance for pediatric acute leukemias: insights from a Brazilian institution with a Latin American perspective.Frontiers in oncology · 2025Article
- Hematopoietic stem cell microtransplantation: current situation and challenges.Therapeutic advances in hematology · 2025Review
- Maintenance Therapy Post-Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia.Current oncology (Toronto, Ont.) · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 1 country.
Funding
Abstract
Acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) are usually associated with poor outcomes, especially in high-risk AML/MDS. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only curative option for patients suffering from high-risk AML/MDS. However, many patients relapse after allo-HSCT. Novel therapy to prevent relapse is urgently needed. Both the BCL-2 inhibitor venetoclax (VEN) and the hypomethylating agent decitabine (DEC) possess significant antitumor activity effects against AML/MDS. Administration of DEC has been shown to ameliorate graft-versus-host disease (GVHD) and boost the graft-versus-leukemia (GVL) effect post-transplantation. We therefore conducted a prospective study (ChiCTR1900025374) to examine the tolerability and efficacy of a maintenance therapy of low-dose decitabine (LDEC) plus VEN to prevent relapse after allo-HSCT for high-risk AML/MDS patients. Twenty patients with high-risk AML (n = 17) or high-risk MDS (n = 3) post-transplantation were recruited. Approximately day 100 post-transplantation, all patients received LDEC (15 mg/m
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.